Abstract 4366487: Artificial Intelligence-Enabled Electrocardiogram for the Detection of Elevated Filling Pressure in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Introduction: Diastolic dysfunction is a hallmark of heart failure with preserved ejection fraction, yet echocardiographic grading is challenging in patients with hypertrophic or amyloid cardiomyopathies due to variable structural and functional remodeling. Consequently, there is a need for additional diagnostic tools to identify patients at increased risk of diastolic dysfunction and enhanced filling pressure. Research Question: What is the accuracy of an artificial intelligence (AI)-enabled electrocardiogram (ECG) model to predict diastolic dysfunction in hypertrophic and amyloid cardiomyopathy? Methods: We included patients with diverse phenotypes of hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis and validated Mayo Clinic's AI-enabled ECG model to grade diastolic function (normal: grade 0/1; abnormal: grade 2/3). Echocardiographic analysis of systolic (LVEF) and diastolic function was performed within 14 days of ECG recording. Diastolic function was graded based on E/e’ (>14), left atrial volume index (>34 mL/m2), pulmonary venous atrial reversal flow duration (≥30 ms), and peak tricuspid regurgitation velocity (>2.8 m/s). Filling pressure was considered increased if ≥3 parameters were abnormal, inconclusive if 2 were abnomal, and normal if ≥3 were normal. Echocardiograms with severe mitral regurgitation were excluded. Results: We identified and matched 840 ECGs from non-obstructive HCM patients (n=125, age 58±19y, 70% male), 145 ECGs from obstructive HCM patients (n=29, age 56±18y, 66% male), 225 ECGs from apical HCM patients (n=33, age 66±14y, 61% male), and 382 ECGs from cardiac amyloidosis patients (n=49, age 70±13y, 57% male). The AI-enabled ECG model predicted diastolic dysfunction with an accuracy of 65% (non-obstructive HCM), 67% (obstructive HCM), 65% (apical HCM), and 75% (cardiac amyloidosis), with sensitivities of 94% and 97% for obstructive HCM and cardiac amyloidosis, respectively, and high positive and negative predictive values for cardiac amyloidosis. Systolic dysfunction (LVEF≤40%) was more common in cardiac amyloidosis (29%) than in all HCM patients (5%). Conclusion: The AI-enabled ECG model demonstrates moderate accuracy but high sensitivity for detecting diastolic dysfunction and increased filling pressure, especially in obstructive HCM and cardiac amyloidosis. The AI-enabled ECG is a useful, widely scalable, and low cost tool to identify patients at increased risk for diastolic dysfunction.